U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family
The latest draft of a U.S. biosecurity law would give drug companies until 2032 to cut their ties with Chinese contract suppliers, allowing WuXi companies time to focus on Europe…
WuXi Bio prescribes share buyback to relieve revenue pain
The pharma services provider has shocked investors with a steep downward revision of its earnings outlook, slashing its full-year revenue growth forecast to just 10% from an initial 30% and…
Recent Articles
U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family
2269.HK
2359.HK
2268.HK
RELATED ARTICLES
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK -
A Drug Company’s Forced Sales, and a Family Feud in Shanghai
2269.HK 2359.HK
-
BRIEF: WuXi AppTec sells advanced therapies units in U.K. and U.S.
2359.HK 603259.SHG
-
Xiaocaiyuan sets the table for Hong Kong IPO. But is the timing right?
0999.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
- Dmall shops for investors, even as business remains mostly a family affair
